Clinical Trials Logo

Cough clinical trials

View clinical trials related to Cough.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06108271 Active, not recruiting - Cough Clinical Trials

Innovative Endotracheal Tube Design Reduces Postoperative Laryngeal Injury

Triglotix®
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized clinical trial is to compare two different orotracheal tubes in patients which require orotracheal intubation for general anesthesia. The main questions it aims to answer are: - To assess the presence of laryngeal injury - To evaluate the consequences in voice quality - To ask for the presence of symptoms as sore throat, hoarseness, and cough Participants will be randomly assigned into two groups, one will use conventional endotracheal tube and the other will use Triglotix® endotracheal tube.

NCT ID: NCT05723159 Active, not recruiting - Cough Clinical Trials

Clinical Validation of the Hyfe Cough Monitoring System

Start date: March 10, 2023
Phase:
Study type: Observational

This is a multicenter observational study and will include individuals with a variety of cough related conditions including but not limited to refractory chronic cough, Chronic Obstructive Pulmonary Disease (COPD) and non-tuberculous mycobacteria. The primary objective of this study is to assess the overall performance of the Hyfe Cough Monitoring System (HCMS, Hyfe Inc., 2022) when used by individuals with problematic cough, under common living conditions.The monitoring period for outpatients will be 24 hours.

NCT ID: NCT05479929 Active, not recruiting - Cough Clinical Trials

Work of Breathing Assessment in Triage Scale

Start date: October 30, 2020
Phase:
Study type: Observational

The proposed research study will be a prospective observational study designed to validate the Canadian Triage Assessment Scale (CTAS) in regard to work of breathing in patients in the emergency department. The investigators will assess inter-rater agreement between nurses & emergency physicians for assessment of work of breathing.

NCT ID: NCT05185089 Active, not recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

IPF-COMFORT
Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.

NCT ID: NCT04882943 Active, not recruiting - Clinical trials for Refractory Chronic Cough

COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database

COREC
Start date: May 6, 2021
Phase:
Study type: Observational

Chronic cough (TC), defined by a duration exceeding 8 weeks, is a particularly frequent symptom with a prevalence observed at 9.6% 1. Chronic cough is the cause of a major handicap for patients with a impact on their quality of life 2. Although CT is common, management is often delicate and complex. In studies, asthma, gastroesophageal reflux disease, posterior flushing, rhino-sinusitis, or taking tussigenic medications are common causes of chronic coughs. However, chronic refractory or unexplained cough, which corresponds to cough for which no cause has been found or the treatments directed against the cause of the cough have not made it possible to resolve the cough, is a real problem in practice. nick3. There is currently no prospective data in France on the characteristics of chronic cough (etiologies, response to treatment) and the percentage of refractory cough. The aim of the study is to constitute a French prospective multicenter hospital cohort of chronic cough patients in order to identify, for the first time in France in a prospective and multicenter manner, the frequency of patients with refractory cough among chronic cough patients.

NCT ID: NCT04125563 Active, not recruiting - Cough Clinical Trials

Influence on Cough and Airway Symptoms by Oral Capsaicin

Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

Study objectives To establish whether an oral intake of Capsicum oleoresin; capsaicinoids expressed as 0.4 mg capsaicin (C18H27N03; Mw: 305.4) in each capsule (from chili extract) can desensitise the cough reflex and improve unexplained coughing. Study period - Estimated Start date (first patient enrolled) June 2019 - Estimated End date (last patient completed follow up) June 2020 - First data available for presentation September 2020 Investigational product/comparator The formulation is prepared from Capsicum oleoresin. Each capsule will contend a dose corresponding to 0.4 mg capsaicin. All test methods are as per the European Pharmacopoeia for Capsicum oleoresin refined and standardised. - The formulation is developed by Research Institutes of Sweden (RISE), Sodertalje, Sweden - Supplier of raw material for the Capsicum oleoresin product/IMP: RANSOM; Ltd, London, UK - Producer of capsules with Capsicum oleoresin and placebo: by Catalent Pharma Solutions, St Petersburg, Florida, USA - Packing bottles of capsules with the investigational medical product (IMP) and placebo: by Apotek Produktion & Laboratorier AB (APL), Stockholm, Sweden Study design Capsules, taken orally, with standardised doses of Capsicum oleoresin corresponding to 0.4 mg pure capsaicin (from chili extract) in each capsule in comparison to matched capsules with placebo (sorbitol and colorant), all capsules looking the same. Four weeks of active treatment is compared to four weeks of placebo. In between there is a wash out period of two weeks. The time frame is 24 hours + 10 weeks. During the first 24 hours the patients carry a cough recorder (Leicester Cough Monitor - LCM) and then start with 4 weeks of active treatment or placebo. This is followed by 2 weeks of wash out and then the patients start with another 4 weeks of active treatment or placebo. After this the study ends. Collaboration Professor Alyn Morice MD, PhD, chief physician at Hull York Medical School, University of Hull, UK. Professor Surinder Birring MD, Senior Lecturer, specialist in respiratory medicine, Imperial College, London, UK. Associate professor Alastair Ross,PhD, Chalmers University of Technology, Gothenburg, Sweden. Study center and number of subjects planned All clinical trials take place at the asthma and allergy clinic, Sahlgrenska University Hospital, Gothenburg, Sweden from where 60 patients with chronic idiopathic cough (CIC) are recruited.

NCT ID: NCT02065440 Active, not recruiting - Cough Clinical Trials

The Effect of Ebastine/Pseudoephedrine on Subacute Cough

Start date: September 2011
Phase: N/A
Study type: Interventional

To determine whether ebastine/pseudoephedrine is effective on subacute cough.

NCT ID: NCT01279668 Active, not recruiting - Whooping Cough Clinical Trials

Montelukast for Persistent Cough in Young People and Adults

MAC
Start date: May 2011
Phase: Phase 4
Study type: Interventional

Persistent cough is a common symptom, accounting for about 20% of referrals to outpatient chest clinics. Most coughs are caused by self-limiting viral infections such as the common cold. However, 1 in 4 people with a viral infection develop a persistent cough, which can go on for several weeks. Whooping cough is a common cause of persistent cough in young people and adults. Although the whooping cough vaccine gives lifelong protection against severe infection, it does not appear to give such long-term protection against milder infections, which can make someone cough for many weeks. There are currently no proven efficacious treatments for persistent cough following either a viral infection or infection with whooping cough. Montelukast is a medication which is already licensed for the treatment of asthma. It works by blocking the action of chemicals called leukotrienes, which make the airways of people with asthma inflamed and sensitive. There is strong evidence to suggest that leukotrienes are also involved in causing persistent cough following viral or whooping cough infection. Montelukast may therefore also help settle persistent coughs in these settings. Over 18 months, we will recruit patients aged 16-49 years with a cough lasting 2-8 weeks from general practices in England. An oral fluid sample will be taken from each participant to be tested for whooping cough. Participants will be randomly allocated to receive a 28-day course of montelukast or placebo tablets and asked to complete a daily cough diary for two weeks. They will be assessed after two weeks by their GP (face-to-face) and after four weeks by another member of practice clinical staff (telephone). Some participants will be given a 24-hour cough monitor to wear on study entry and at two-week follow-up. This study will be funded by the National Institute for Health Research's School of Primary Care.

NCT ID: NCT00131157 Active, not recruiting - Asthma Clinical Trials

Evaluation of Spirometry Expert Support in General Practice

Start date: January 2003
Phase: N/A
Study type: Interventional

More and more general practitioners (GPs) use spirometry in their practices. At this time, there is sufficient reason to presume that, after a single postgraduate training program without any further support, most GPs have insufficient knowledge and ability to assure valid interpretation of their spirometry tests. Therefore, some kind of continuous diagnostic support with regard to spirometry interpretation by GPs is advisable. The aim of the present study is to assess whether implementation of spirometry expert support (either by a computerised expert system or a working agreement between general practitioners and respiratory consultants with respect to spirometry interpretation) causes changes in diagnosing and appropriateness and efficiency of medical care in subjects with chronic respiratory morbidity managed in general practice.